BUZZ-Ionis Pharma rises on better-than-expected quarterly results

Drugmaker Ionis Pharmaceuticals' IONS.O shares rise 4.5% to $33.40 premarket

IONS posts Q4 sales of $227 mln, above analysts' est of $137.6 mln - LSEG

Co reports Q4 loss of 66 cents/share vs analysts' est loss of $1.12/share - LSEG

Co expects 2025 rev to be over $600 mln; analysts on avg expect 2025 rev to be $676 mln - LSEG

As of December 31, 2024, IONS had cash, cash equivalents and short-term investments of $2.3 bln

Co forecasts cash, cash equivalents and short-term investments of about $1.7 bln for 2025

IONS fell ~34% in 2024